Specifically, the present study aimed to assess the influence of the CYP2D6 and CYP1A2 gene polymorphisms on the effectiveness of duloxetine in reducing depressive and anxiety symptoms among patients with MDD. Here, CYP1A2 is linked to major depressive disorder.